Several studies highlight the high efficacy of guselkumab (anti-IL23) and secukinumab (anti-IL17) for the control of severe psoriasis, in addition to the control of psoriatic arthritis symptoms [13], which other older biologics do not resolve. Here, IL17A is linked to psoriatic arthritis.